Radius Health, Inc. (NASDAQ:RDUS) shares gapped down before the market opened on Monday after Jefferies Group lowered their price target on the stock from $38.00 to $31.00. The stock had previously closed at $30.12, but opened at $29.56. Jefferies Group currently has a hold rating on the stock. Radius Health shares last traded at $28.92, with a volume of 567093 shares trading hands.

RDUS has been the subject of a number of other research reports. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub downgraded shares of Radius Health from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research report on Sunday, July 23rd. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. Finally, Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Radius Health currently has a consensus rating of “Hold” and a consensus price target of $51.00.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction that occurred on Tuesday, September 5th. The shares were purchased at an average cost of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the purchase, the insider now directly owns 5,298,799 shares of the company’s stock, valued at approximately $194,730,863.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of Radius Health stock in a transaction that occurred on Thursday, August 10th. The shares were purchased at an average price of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the purchase, the insider now directly owns 5,113,799 shares of the company’s stock, valued at $178,829,551.03. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 519,100 shares of company stock valued at $17,970,882. Company insiders own 15.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sei Investments Co. lifted its stake in Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Radius Health by 19.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares during the last quarter. Advisor Group Inc. lifted its stake in Radius Health by 267.2% during the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,888 shares during the last quarter. Blair William & Co. IL bought a new position in Radius Health during the second quarter worth $205,000. Finally, Amalgamated Bank bought a new position in Radius Health during the second quarter worth $211,000.

The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the previous year, the company earned ($1.07) earnings per share. equities research analysts expect that Radius Health, Inc. will post -5.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Radius Health, Inc. (RDUS) Shares Gap Down Following Analyst Downgrade” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/radius-health-inc-rdus-shares-gap-down-following-analyst-downgrade/1683523.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.